



2011-01-01

Water-soluble CuII and MnII bis-phenanthroline octanedioate complexes with unprecedented nano and picomolar in vitro cytotoxicity as promising leads for chemotherapeutic drug development

Andrew Kellett
Dublin Institute of Technology

Mark O'Connor
Dublin Institute of Technology

Malachy McCann
NUI Maynooth

Orla Howe
Dublin Institute of Technology

Alan Casey
Dublin Institute of Technology

See next page for additional authors

Follow this and additional works at: <http://arrow.dit.ie/materart>

 Part of the [Chemistry Commons](#)

Recommended Citation

Kellett, Andrew; O'Connor, Mark; McCann, Malachy; Howe, Orla; Casey, Alan; McCarron, Pauric; Kavanagh, Kevin; McNamara, Mary; Kennedy, Sean; May, Donald D.; Skell, Philip S.; O'Shea, Denis; and Devereux, Michael, "Water-soluble CuII and MnII bis-phenanthroline octanedioate complexes with unprecedented nano and picomolar in vitro cytotoxicity as promising leads for chemotherapeutic drug development" (2011). *Articles*. Paper 12.
<http://arrow.dit.ie/materart/12>

This Article is brought to you for free and open access by the Materials Synthesis and Applications at ARROW@DIT. It has been accepted for inclusion in Articles by an authorized administrator of ARROW@DIT. For more information, please contact yvonne.desmond@dit.ie, arrow.admin@dit.ie.



Authors

Andrew Kellett, Mark O'Connor, Malachy McCann, Orla Howe, Alan Casey, Pauric McCarron, Kevin Kavanagh, Mary McNamara, Sean Kennedy, Donald D. May, Philip S. Skell, Denis O'Shea, and Michael Devereux

Water-soluble Cu^{II} and Mn^{II} bis-phenanthroline octanedioate complexes with unprecedented nano and picomolar *in vitro* cytotoxicity as promising leads for chemotherapeutic drug development

Andrew Kellett,^{*a} Mark O'Connor,^a Malachy McCann,^b Orla Howe,^a Alan Casey,^a Pauraic McCarron,^{a,b} Mary McNamara,^a Sean Kennedy,^a Donald D. May,^c Philip Skell,^d Denis O'Shea^a and Michael Devereux^{a,*}

Received (in XXX, XXX) Xth XXXXXXXXX 200X, Accepted Xth XXXXXXXXX 200X

First published on the web Xth XXXXXXXXX 200X

DOI: 10.1039/b000000x

Dinuclear Cu^{II} and Mn^{II} bis-phenanthroline octanedioate complexes exhibit rapid, unprecedented nano and picomolar *in vitro* cytotoxicity against colorectal cancer lines and are less toxic than cisplatin when examined *in vivo*. The complexes are potent generators of cellular reactive oxygen species, avid DNA binders and induce O₂ dependent cleavage of DNA. The Cu(II) complex was found to have self-cleaving nuclease activity.

Introduction

The development of self-cleaving chemical nucleases is regarded as the paradigm of redox-active metal-based chemotherapeutics. DNA targeted agents capable of inducing single stranded or double stranded scission have found clinical application within cancer chemotherapy.¹ Other applications within this class include; probing of DNA-specific structures, mapping of protein and DNA interactions, gene regulation and signal transduction.^{2,3} Thus, explorations toward the discovery and development of natural or synthetic chemical nucleases are major topics of interest. Redox active transition-metal-based chemical nucleases are particularly important due to their catalytic potential to support the one-electron oxidation/reduction reactions necessary to drive activation of C-H deoxyribose bonds.

In the presence of Cu²⁺, the oxidative formation of π radical cations within marine-based products tambjamine E,⁴ prodigiosin⁵ and pyrimol,⁶ have recently been shown to mediate self-cleaving DNA damage, i.e. scission which does not require the presence of added oxidant or reductant. These Cu²⁺ compounds have also demonstrated significant *in vitro* chemotherapeutic potential against leukaemia and ovarian cancer cells, some of which had cisplatin resistance.^{5,6}

The discovery of the first synthetic chemical nuclease, [Cu(phen)₂]²⁺ (phen = 1,10-phenanthroline, **Figure 1**), has sparked intensive effort toward the development of new bis-phen agents capable of enhanced DNA cleaving compared to the parent complex.⁷ The DNA cleaving limitations of [Cu(phen)₂]²⁺ include (i) a high dissociation constant of the second coordinated phenanthroline ligand⁸ and (ii) the need for exogenous reductant to generate the active species [Cu(phen)₂]⁺. The dissociation problem (i) was solved by Meunier, Pitie *et al* through the advent of clip-phen, whereby two phenanthroline ligands are connected at the 2' or 3' position by a serinol bridge.⁹⁻¹¹ Recently this laboratory has reported the first self-cleaving bis-phen system, [Cu(phen)₂(phthalate)] (phthalate = *o*-, *m*-, *p*-phthalate, **Figure 1**), capable of inducing single-stranded DNA scission in the absence of exogenous reductant or oxidant.¹²

While [Cu(phen)₂(phthalate)] complexes displayed excellent chemotherapeutic potential against, colon (HT29), breast (MC-F7) and prostate (DU145) cancer lines, their water solubility is poor. Of the phthalate group, the cationic, dinuclear species [Cu₂(phen)₄(μ_2 -*p*-phthalate)]²⁺ was the most active DNA-binding, self-cleaving and chemotherapeutic agent. To that end, in the current study, we have investigated the application of water soluble Cu²⁺ and Mn²⁺ dinuclear, cationic, bis-phen octanedioate (oda) (**Figure 1**) systems as nuclease mimetics and their ability to induce cancer cell death through the redox-generation of reactive oxygen species (ROS). The possible formation of a π carboxyl radical within the Cu²⁺ system, which cleaves DNA by self-activation, is also discussed.




Figure 1. Molecular structures of phen, odaH₂ and the phthalates

The title complexes [Cu₂(μ_2 -oda)(phen)₄](ClO₄)₂ (**1**) (**Figure 2**), [Mn₂(μ_2 -oda)(phen)₄(H₂O)₂(oda)₂]²⁺[Mn₂(μ_2 -oda)(phen)₄(H₂O)₂]²⁺ (**2**) (**Figure 3**), were prepared according to the literature methods by McCann and Devereux *et al.*^{13,14} The coordination environment about both Cu²⁺ ions in **1** is approximately square-pyramidal with both metals being linked via a bridging oda ligand. In the double salt complex **2**, the environment about each Mn²⁺ is octahedral with both metals in the cationic and anionic groups being bridged by oda in a similar fashion to **1**. Whereas the Mn²⁺ centres of the anionic subunit in **2** each contain a singly bound oda dianion coordinated in the apical position, the cationic unit contains bound water at these equivalent positions.

Figure 2. Molecular structure the [Cu₂(μ_2 -oda)(phen)₄]²⁺ cation in complex **1**

15 **Figure 3.** Molecular structures of the dimeric cation and anion subunits in the Mn^{II} double salt complex [Mn₂(μ₂-oda)(phen)₄(H₂O)₂(oda)₂]²⁺[Mn₂(μ₂-oda)(phen)₄(H₂O)₂]²⁻ (**2**)

DNA Binding Studies

20 In order to examine the interaction of compounds **1** & **2** with DNA, competitive ethidium bromide displacement and fluorescence quenching experiments with calf thymus DNA were conducted (**Table 1**).[†] Complexes **1** & **2** were found to have high apparent DNA binding constants (K_{app}), and low fluorescence quenching values (Q), indicating that both systems have a high affinity for binding to DNA.

Table 1. Apparent DNA binding constants (K_{app}) and Q values for **1** and **2**.[†] Assay conditions; C_{50}/K_{app} : final volume 2 mL, 1.2 μM EtBr, 1 μM CT-DNAp, 10 mM TES, 0.1 mM Na₂EDTA, pH 7.0; Q : final volume 2 mL, 2.0 μM EtBr, 20 μM CT-DNAp, 2 mM NaOAc buffer, 9.3 mM NaCl, 0.1 mM Na₂EDTA, pH 5.0

Complex	C_{50} [‡] (μM)	K_{app} ^{**}	Q [‡]
1	46.89	2.55×10^5	22.64
2	28.46	4.20×10^5	43.13

[‡] C_{50} = concentration required to reduce fluorescence by 50% (Competitive)

^{**} $K_{app} = K_e \times 1.26/C_{50}$ where $K_e = 9.5 \times 10^6 \text{ M(bp)}^{-1}$

35 [‡] Q = equivalent concentration required to reduce fluorescence by 50% (Quenching)

DNA Cleavage Reactions

Relaxation of supercoiled (SC) pUC18 DNA (Form I) into open circular (OC, Form II) and linear (LC, Form III) conformations was used to quantify the relative cleavage efficiency of **1** & **2**.[†] To examine for DNA self-cleaving ability, SC DNA was exposed to both complexes over a concentration range of 1–50 μM for 20 hours in the absence of added H₂O₂ or reductant (**Figure 4(a)**). Complex **1** shows concentration-dependant self-cleaving of SC (Form I) DNA to OC (Form II) with complete depletion of the parent SC band (I→II) between 10–20 μM (lane 4 & 5 (*a*)). In the presence of added reductant (ascorbate) (**Figure 4(b)**) both complexes exhibit enhanced DNA scission during a shorter time-frame (2hr). While both **1** & **2** induced complete relaxation to OC Form II (lanes 4 & 8 (*b*)) at 10 μM, the Cu²⁺ complex was found to induce efficient double stranded scission (I→III) at a concentration of 20 μM, characterised by the absence of a band in lane 5 (*b*). In order to identify what role molecular O₂ and the metal cations (Cu²⁺/Mn²⁺) play within DNA cleavage, experiments were conducted under anaerobic conditions in an atmosphere saturated with argon and, separately, in the presence of 100 mM Na₂EDTA (**Figure 4 (c) & (d)**). The Mn²⁺ system

was examined at 20 μM over two hours in the presence of ascorbate while the Cu²⁺ system was examined at 20 μM over 20 hr without added reductant. Both complexes did not cleave DNA in the absence of oxygen but complex **1** was found to induce some DNA damage in the presence of excess metal chelator (EDTA).

65 **Figure 4.** Relaxation of pUC18 by **1** and **2**.[†] Cleavage was carried out at 37°C then analyzed by agarose gel electrophoresis.[†] (a) 20hr incubation in the absence of added oxidant or reductant, lane 1: DNA alone; lanes 2–6: 1, 5, 10, 20, 50 μM **1**; lanes 7–10: 5, 10, 20, 50 μM **2**. (b) 2hr incubation in the presence of added ascorbate (at twice complex concentration), lane 1: DNA alone; lanes 2–5: 1, 5, 10, 20 μM **1**; lanes 6–9: 1, 5, 10, 20 μM **2**. (c) 20hr incubation of 20 μM **1** in the absence of added oxidant or reductant, lane 1: + 100 mM Na₂EDTA; lane 2: sat. Ar atmosphere. (d) 2hr incubation of 20 μM **2** with added ascorbate (at twice complex concentration), lane 1: + 100 mM Na₂EDTA; lane 2: sat. Ar atmosphere.

75 Redox Activity






Figure 5. SOD activity profiles for complexes **1** and **2**

Table 2. SOD concentrations of complexes **1** and **2** equivalent to effect 1U of Bovine Erythrocyte SOD activity (50% Inhibition) and Catalase mimetic potential of **1** and **2** examined as a function of H₂O₂ disproportionation

Complex	Concentration Equivalent to 1U Bovine SOD (μM)	Number of H ₂ O ₂ molecules disproportionated by one molecule of complex in the first 5 min ¹⁴
1	1.300	0
2	0.024	6×10^3

Since the catalytic interaction of [Cu(phen)₂]²⁺ and its reduced form, [Cu(phen)₂]⁺, with the superoxide radical (O₂^{•-}) and hydrogen peroxide (H₂O₂) are imperative for cleaving the phosphodiester backbone in DNA,^{15–17} we have examined the interaction of complexes **1** and **2** with both these species. Superoxide was generated enzymatically by the xanthine/xanthine-oxidase system and quantified photometrically by the detector nitro-blue-tetrazolium (NBT). Both complexes **1** and **2** show potent SOD (superoxide dismutase) mimetic activity with the Mn²⁺ system being an exceptional catalyst (1U SOD = 24.6 nM) (**Figure 5 & Table 2**). The catalase mimetic activity of complexes **1** & **2** were examined as a function of oxygen evolution. After the addition of a 30% v/v solution of H₂O₂ to **1** & **2** the O₂ gas evolved was quantified volumetrically (**Table 2**). Only the Mn²⁺ complex (**2**) was capable of decomposing H₂O₂ and its activity can also be described as exceptional in this regard (6×10^3 H₂O₂ molecules disproportionated in 5 min). Overall, both complexes **1** & **2** interacted with superoxide to produce hydrogen peroxide (I), but, only the Mn²⁺ complex (**2**) appears capable of disproportionates the resulting peroxide (II).



Antitumour Activity

Table 3. LD₅₀ (at ± 95% CI) values for complexes **1** and **2**, the free ligand phen and the antitumour agent cisplatin, against colorectal cancer lines HT29, SW480 and SW620 over a period of 24 and 96 hours[†] **Alan do we need ±SD values here? Also can you include the HaCaT results here?**

	Antitumour Activity LD ₅₀ (μM)					
	HT29		SW480		SW640	
	24 hr	96 hr	24 hr	96 hr	24 hr	96 hr
phen	<200	9.240	<200	10.70	160.00	10.700
1	9.610	>0.001	11.30	0.220	31.00	1.220
2	108.00	0.092	7.460	0.261	58.50	0.342
cisplatin	166.00	4.810	<200	1.290	<200	7.030

The cytotoxicity of **1** & **2** along with the free phen ligand and the clinical antitumour agent cisplatin, were measured at 24 and 96hr intervals using a standard MTT assay against three progressive colorectal human-derived tumour cell lines (**Table 3**).[†] Both complexes display remarkable cytotoxicity against all three lines. Low-micromolar LD₅₀ activities for both complexes were found after 24 hrs of exposure and, significantly, these activities reached the nano- and picomolar level after 96 hrs. As the colorectal tumour lines progress (HT29→SW480→SW620) activity of complex **1**, over 96hrs, reduces from pico- to low micromolar, while the activity of **2** remained consistently in the low-mid nanomolar region. It is worth noting that while cisplatin displays significant low-micromolar cytotoxicity against all tumour lines after 96hrs, the activity of **1** & **2**, in this period, is superior to this agent by a factor between 1x10¹ – 1x10⁵.

Cellular Reactive Oxygen Species (ROS) Study

In order to elucidate the relationship between cytotoxicity and ROS generation, complexes **1** & **2**, along with phen and cisplatin, were exposed to colorectal cancer cells, HT29, pre-treated with the intracellular ROS indicator 2',7'-dichlorofluorescin diacetate (DCFH-DA).[†] In the presence of endogenously generated ROS, DCFH-DA becomes oxidised to release the fluorophore 2',7'-dichlorofluorescin (DFC). Results are expressed relative to the fluorescent response of the positive control (+Ctrl), hydrogen peroxide, which is considered a potent generator of ROS. Corrections were made using a negative control (-Ctrl), which represents the natural level of cellular ROS generated. Results were recorded at 15, 30, 60, 120 and 180 min intervals and are shown in **Figure 6**. Complex **2** was found to be an exceptional generator of ROS with greater activity relative to H₂O₂ (+Ctrl) across the concentration range 1000-250 nM and approximate equal activity to peroxide at 125 nM. It is worth commenting that this species was almost seven times more active than the next most effective ROS generator, phen. The activity of the copper(II) complex (**1**) was somewhat lower than both free phen and complex **2**, indeed **1** needed to be assessed across a higher concentration range (100,000-195 nM). The clinical agent cisplatin was the least active of all tested compounds. This is unsurprising considering it is non-catalytic, it has also been well established that cisplatin only becomes cytotoxic upon its hydrolysis to [Pt(NH₃)₂(OH)₂], which generally occurs between 48-96 hrs.

Figure 6. Generation of endogenous reactive oxygen species (ROS) within the cancer cell line HT29 after exposure to; (a) the free ligand 1,10-phenanthroline, (b) the clinical antitumour agent cisplatin, (c) complex **1** and (d) complex **2**.

In vivo Drug Tolerance

Larvae of the insect *Galleria mellonella* were employed to assess the *in vivo* cytotoxic tolerance of complexes **1** and **2**, the ligand phen and the clinical antitumour agent cisplatin. Larvae of *G. mellonella* (the greater wax moth) have been widely used as a convenient and inexpensive *in vivo* screening model to assess the therapeutic potential of novel antimicrobial drugs.^{18, 19} They have yielded results that are considered comparable to those obtained using mammalian models.²⁰ The innate defences of insects, including *G. mellonella*, like those of mammals consist of structural and passive barriers as well as humoral and cellular responses within the haemolymph (analogous to the blood of mammals).²¹ Indeed cellular responses within the haemolymph are often activated by signal transduction systems comparable to mice.²²

Table 4. % Kill of *G. mellonella* larvae after exposures of 5000-100 μg/mL of complexes **1** and **2**, the ligand phen and the clinical antitumour drug cisplatin over the period 72 hours[†] **Pauraic/Malachy we need to include ±SD values in this table.**

	% Kill of <i>Galleria mellonella</i> larve (72 hr)				
	Concentration μg/mL (mg/kg body weight)				
	5000 (333)	2000 (133)	1000 (67)	500 (33)	200 (13)
phen	100	90	80	0	0
1	93.3	86.7	50	0	0
2	93.3	93.3	40	0	0
cisplatin	100	100	100	60	0

Testing was carried out in triplicate using ten healthy *G. mellonella* larvae in the 6th developmental stage. Compounds were tested across the concentration range 5000-100 μg/mL (333-13 mg/kg average body weight) with sterile test solutions being administered via hypodermic injection. Larvae were incubated at 30°C for 72 hr with survival being monitored at 24 hr intervals and significance being determined using the log rank (Mantel-Cox) method. Death was assessed by the lack of movement in response to stimulus together with discolouration. Results are presented (**Table 4**) as the mean % kill (± standard deviation) resulting from exposure to tested compound. *Galleria* exposed to high drug concentrations of 5000 and 2000 μg/mL showed poor tolerance to all tested species. However, at lower concentration ranges 1000-200 μg/mL significant differences were observed. Tolerance of *Galleria* larvae exposed to complexes **1** and **2** was highest of all tested species (50 and 40% kill at 67 mg/kg respectively, and 0% kill at 33 mg/kg). The clinical antitumour agent cisplatin was the poorest tolerated tested species with high toxicity (60% kill) being observed at 500 μg/mL (33 mg/kg). Encouragingly, the well-established rat LD₅₀ of cisplatin (oral exposure) is reported as 25.8 mg/kg body weight, thus, it appears some agreement between these two models does exist.

Proposed DNA Self-Cleaving Mechanism

To conclude we would like to propose a mechanism by which of complex **1** self-activates the phosphodiester backbone in DNA via formation of a π carboxylate radical, concomitantly leading to the reduced formation of [Cu(phen)₂]⁺ (**Figure 7**). Aliphatic carboxylate radicals are known to react by hydrogen abstraction in close competition with decarboxylation.^{23, 24} Generation of a π carboxylate radical within complex **1** would depend on the strength of the HOMO *d* orbital overlap on Cu²⁺ with the oxygen carboxylate. X-ray crystallography has revealed that the bond length between Cu-O in **1** is 1.974Å and is significantly shorter than the equivalent Mn-O bond in **2** which is 2.147 Å.^{13, 14}

However, since the Cu-O bond length may be altered when **1** binds with DNA, it is impossible to know its exact length *in vivo*.




Figure 7. Proposed mechanism of generating C-H bond activators (---)

It is proposed the mechanism proceeds by the following steps: (i) after the binding of **1** to DNA, homolytic cleavage at the Cu-O bond generates the π carboxyl radical (---) and the reduced d^{10} complex $[\text{Cu}(\text{phen})_2]^+$, the resultant carboxyl π radical undergoes rapid conversion to σ which decarboxylates to generate CO_2 and R^* (---); (ii) $[\text{Cu}(\text{phen})_2]^+$ reacts, as is known, with O_2 to generate the superoxide radical through an intermediate (---) yielding $[\text{Cu}(\text{phen})_2]^{2+}$; (iii) complex **1** or $[\text{Cu}(\text{phen})_2]^{2+}$ subsequently react with $\text{O}_2^{\bullet-}$ to generate H_2O_2 (as shown in **Figure 5** & **Table 2**); (iv) since **1** does not disproportionate hydrogen peroxide (shown in **Table 2**) a subsequent reaction with H_2O_2 in (a) or O_2 in (b) can generate known metal-oxo (---) and hydroxyl radical (---) bond activators. Since nuclease activity was detected in the presence of the chelator EDTA (**Figure 4 (c)**) it would stand to reason that the carboxylate radical or its breakdown product (R^*) appears capable of abstracting H^* from the phosphodiester backbone in DNA. In the absence of oxygen, the self-cleaving nuclease potential of **1** is diminished (**Figure 4 (c)**), and since, in the proposed mechanism, steps (ii)-(iv) are dependant on molecular oxygen, it also stands to reason that the nuclease potential should be reduced in the absence of these aerobically generated oxo- and hydroxo- bond activators. Further efforts are currently underway in our laboratory to find further evidence for this proposed mechanism.

Conclusions

In summary, dinuclear Cu^{2+} and Mn^{2+} bis-phen complexes of the dicarboxylate, octanedioate, represent a significant advancement compared to existing metal-phenanthroline adducts. Their application as new water-soluble DNA-targeted chemotherapeutics is highly significant given their powerful and unprecedented cytotoxicity, encouraging *in vivo* drug tolerance and unique modes of action. While both complexes are avid binders of DNA, additionally, the copper(II) system has the capacity to self-cleave DNA, possibly through the generation of a π carboxyl radical, while the manganese(II) system is an exceptional redox catalyst that generates unprecedented levels of intracellular ROS within colon cancer cells.

The authors wish to acknowledge financial support from the Dublin Institute of Technology Capacity Building

Scheme for Strategic Research programme (CaBS). This work has been carried out (in part) within the structures of the Focas Research Institute, DIT, funded under The Irish National Development Plan with assistance from the European Regional Development Fund.

Notes and references

^a Dublin Institute of Technology, Focas Research Institute, Camden Row, Dublin 8, Ireland. E-mail: andrew.kellett@dit.ie, Tel: +353 1 4027986; E-mail: michael.devereux@dit.ie, Tel: +353 1 4024680

^b Chemistry Department, National University of Ireland, Maynooth, Co. Kildare, Ireland

^c ???

^d ???

† Electronic Supplementary Information (ESI) available: Experimental procedures, X-ray crystallographic data and biological evaluation studies See DOI: 10.1039/b000000x/

1. J. Stubbe and J. W. Kozarich, *Chem. Rev.*, 1987, **87**, 1107-1136.
2. F. Mancin, P. Scrimin, P. Tecilla and U. Tonellato, *Chem Commun (Camb)*, 2005, 2540-2548.
3. J. A. Cowan, *Current Opinion in Chemical Biology*, 2001, **5**, 634-642.
4. S. Borah, M. S. Melvin, N. Lindquist and R. A. Manderville, *J. Am. Chem. Soc.*, 1998, **120**, 4557-4562.
5. M. S. Melvin, J. T. Tomlinson, G. R. Saluta, G. L. Kucera, N. Lindquist and R. A. Manderville, *J. Am. Chem. Soc.*, 2000, **122**, 6333-6334.
6. P. U. Maheswari, S. Roy, H. den Dulk, S. Barends, G. van Wezel, B. Kozlevcar, P. Gamez and J. Reedijk, *J. Am. Chem. Soc.*, 2006, **128**, 710-711.
7. D. S. Sigman, D. R. Graham, V. D'Aurora and A. M. Stern, *J. Biol. Chem.*, 1979, **254**, 12269-12272.
8. B. R. James and R. J. P. Williams, *J. Chem. Soc.*, 1961, 2007-2019.
9. M. Pitie, B. Donnadiou and B. Meunier, *Inorg. Chem.*, 1998, **37**, 3486-3489.
10. M. Pitie and B. Meunier, *Bioconjug Chem*, 1998, **9**, 604-611.
11. M. Pitie, B. Sudres and B. Meunier, *Chem. Comm.*, 1998, 2597-2598.
12. A. Kellett, M. McCann, M. O'Connor, M. McNamara, P. Lynch, G. Rosair, V. McKee, B. Creaven, M. Walsh, S. McClean, A. Foltyn, D. O'Shea, O. Howe and M. Devereux, *Dalton Trans.*, 2010, DOI: 10.1039/C0DT01607A.
13. M. Devereux, M. McCann, J. F. Cronin, G. Ferguson and V. McKee, *Polyhedron*, 1999, **18**, 2141-2148.
14. M. T. Casey, M. McCann, M. Devereux, M. Curran, C. Cardin, M. Convery, V. Quillet and C. Harding, *Chem. Comm.*, 1994, 2643-2645.
15. L. E. Marshall, D. R. Graham, K. A. Reich and D. S. Sigman, *Biochemistry*, 1981, **20**, 244-250.
16. T. B. Thederahn, M. D. Kuwabara, T. A. Larsen and D. S. Sigman, *J. Am. Chem. Soc.*, 1989, **111**, 4941-4946.
17. B. C. Bales, T. Kodama, Y. N. Weledji, M. Pitie, B. Meunier and M. M. Greenberg, *Nucleic Acids Res*, 2005, **33**, 5371-5379.
18. M. Brennan, D. Y. Thomas, M. Whiteway and K. Kavanagh, *FEMS Immunol Med Microbiol*, 2002, **34**, 153-157.
19. R. Rowan, C. Moran, M. McCann and K. Kavanagh, *Biometals*, 2009, **22**, 461-467.
20. K. Kavanagh and E. P. Reeves, *FEMS Microbiol Rev*, 2004, **28**, 101-112.
21. G. B. Dunphy and G. S. Thurston, *Insect Immunity*, CRC Press, Boca Raton, FL., 1990.
22. A. M. Fallon and D. Sun, *Insect Biochem Mol Biol*, 2001, **31**, 263-278.
23. P. S. Skell and D. D. May, *J. Am. Chem. Soc.*, 1981, **103**, 967-968.
24. P. S. Skell and D. D. May, *J. Am. Chem. Soc.*, 1983, **105**, 3999-4008.